Ivosidenib, an IDH1 inhibitor, has shown efficacy, as demonstrated in the ClarIDHy trial,82 where it significantly improved mPFS from 1.4 months to 2.7 months, resulting in FDA approval for use in IDH1-mutated CCA.83 This evidence concerns the gene IDH1 and cholangiocarcinoma.